Ciclopirox is under clinical development by ATLAS Molecular Pharma and currently in Phase I for Porphyria (Erythropoietic Protoporphyri). According to GlobalData, Phase I drugs for Porphyria (Erythropoietic Protoporphyri) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ciclopirox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ciclopirox overview
Ciclopirox is under development for the treatment of congenital erythropoietic porphyria. It is a repositioned drug developed based on the chaperone seeker system (CHASSYS) platform technology. It is administered through oral route.
ATLAS Molecular Pharma overview
ATLAS Molecular Pharma is develops new pharmacological chaperones for the treatment of rare metabolic diseases that intends to use the proceeds to advance the clinical development of its ATL-001 candidate for the treatment of congenital erythropoietic
For a complete picture of Ciclopirox’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
